4basebio inks development deal with Heqet Therapeutics
Life sciences company 4basebio announced a joint development agreement with Heqet Therapeutics on Wednesday.
The AIM-traded firm said the agreement would be focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration, and the treatment of myocardial infarction more broadly.
Heqet recently closed an €8m (£6.74m) financing round to progress its development programmes.
It was using its proprietary intellectual property to develop therapies enabling heart regeneration and renewal, thus avoiding scar formation on the heart after a myocardial infarction.
Such scarring could eventually lead to cardiac dysfunction and failure, despite improvements in medical interventions.
Under the agreement, the two companies would evaluate the use of 4basebio’s ‘Hermes’ non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte regeneration.
The successful outcome of the project could lead to the proof-of-concept development of a therapy enabling heart regeneration post infarction.
“We are delighted to be working with Heqet on this novel therapy approach for heart repair following myocardial infarction,” said chief executive and chief scientific officer Dr Heikki Lanckriet.
“This further demonstrates the flexible application of our Hermes targeted delivery technology within the cell and gene therapy markets.”
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.